Standout Papers

Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA ... 2018 2026 2020 2023 262
  1. Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study (2018)
    Suresh S. Ramalingam, Yi Cheng et al. Annals of Oncology

Immediate Impact

2 from Science/Nature 63 standout
Sub-graph 1 of 20

Citing Papers

Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
Non-small-cell lung cancer
2024 Standout
1 intermediate paper

Works of C. Zhou being referenced

1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results
2021
Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
2018 Standout

Author Peers

Author Last Decade Papers Cites
C. Zhou 532 437 195 45 628
Chiara Bennati 492 398 178 40 618
N. B. Leighl 554 490 203 32 739
Tzu‐Hsiu Tsai 461 367 182 17 596
Shunichiro Iwasawa 355 360 182 47 637
Anna Wrona 503 438 172 32 663
Lyudmila Bazhenova 553 525 268 81 729
Yun Fan 399 393 202 43 632
Jang Ho Cho 442 411 168 24 617
Weineng Feng 302 332 190 48 598
K. Park 623 523 211 25 698

All Works

Loading papers...

Rankless by CCL
2026